Effect of Hyperthyroidism Control During Pregnancy on Maternal and Fetal Outcome: A Systematic Review and Meta-Analysis

Jose Mario Alves Junior¹*, Wanderley Marques Bernardo²,³, Laura Sterian Ward⁴ and Danilo Villagelin¹,⁵

¹ Postgraduate Course Internal Medicine, Campinas State University, Campinas, Brazil, ² School of Medicine, University of São Paulo, São Paulo, Brazil, ³ Department of Evidence-Based Medicine, University of São Paulo, São Paulo, Brazil, ⁴ Laboratory of Cancer Molecular Genetics, School of Medicine Sciences, Campinas State University, Campinas, Brazil, ⁵ Endocrinology and Metabolism, Hospital of the Pontifical Catholic University of Campinas (PUC-Campinas), Campinas, Brazil

Context: Although the overt hyperthyroidism treatment during pregnancy is mandatory, unfortunately, few studies have evaluated the impact of treatment on reducing maternal and fetal outcomes.

Objective: This study aimed to demonstrate whether treatment to control hyperthyroidism manifested during pregnancy can potentially reduce maternal-fetal effects compared with euthyroid pregnancies through a systematic review with meta-analysis.

Data Source: MEDLINE (PubMed), Embase, Cochrane Library Central, LILACS/BIREME until May 2021.

Study Selection: Studies that compared, during the gestational period, treated women with hyperthyroidism versus euthyroid women. The following outcomes of this comparison were: pre-eclampsia, abruptio placentae, fetal growth retardation, gestational diabetes, postpartum hemorrhage, low birth weight, stillbirth, spontaneous abortions, premature birth.

Data Extraction: Two independent reviewers extracted data and performed quality assessments. Dichotomous data were analyzed by calculating risk differences (DR) with fixed and random effect models according to the level of heterogeneity.

Data Synthesis: Seven cohort studies were included. The results of the meta-analysis indicated that there was a lower incidence of preeclampsia (p=0.01), low birth weight (p=0.03), spontaneous abortion (p<0.00001) and preterm birth (p=0.001) favouring the euthyroid pregnant group when compared to those who treated hyperthyroidism during pregnancy. However, no statistically significant differences were observed in the...
INTRODUCTION

Hyperthyroidism, considering all causes, occurs in 0.2 to 1.3% of the population in countries where iodine intake is sufficient. Graves’ disease (GD) is the most frequent cause and has a high prevalence in women who often appear in reproductive age (1, 2).

Thyrotoxicosis can manifest in pregnancy in three forms: gestational thyrotoxicosis, subclinical hyperthyroidism, and overt hyperthyroidism. Gestational hyperthyroidism is a short form of thyrotoxicosis caused by hCG’s excessive stimulation of the thyroid gland. It is usually limited to the first trimester of pregnancy. It affects 1-3% of all pregnancies, especially in women with hyperemesis gravidarum and multiple gestations (3). Subclinical hyperthyroidism is defined by TSH under the standard limit with average T4/T3 values, respecting the TSH and T4/T3 pregnancy reference values by trimester (1, 3). Overt hyperthyroidism is rare, occurring in only 0.2% of pregnancies, and GD is its most common cause (3, 4).

Although there is consensus on the need for treatment of overt hyperthyroidism during pregnancy, only a few studies evaluated the impact of this treatment on maternal and fetal endpoints (3, 5–11). Most data are conflicting regarding pregnancy outcomes such as pre-eclampsia, growth restriction, low birth weight, miscarriage, and premature birth. Hence, we aimed to understand better the maternal-fetal effects of treating overt hyperthyroidism with anti-thyroid drugs (ATD) (methimazole and propylthiouracil) during pregnancy, reducing adverse outcomes. The well-known teratogenic effects of ATD are beyond the scope of this review.

METHODS

This study was conducted following the PRISMA statement (12). The research protocol was registered in the International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO) under CRD42021242704.

Database Search

The research was exclusively carried out using electronic databases [Medline (https://pubmed.ncbi.nlm.nih.gov/), EMBASE (https://www.embase.com/), Cochrane Library (https://www.cochranelibrary.com/), and Lilacs/Bireme (https://lilacs.bvsalud.org/)]. Searches for randomized controlled trials (RCTs), non-randomized trials (NRS), prospective or retrospective cohort studies were restricted to articles published in English or Portuguese without time limits. The research was developed following the PICO strategy, as follows: (P) women with hyperthyroidism during pregnancy; (I) antithyroid drugs; (C) euthyroid pregnancies and (O): pre-eclampsia, abruptio placentae, fetal growth retardation, gestational diabetes, postpartum hemorrhage, and stillbirth.

Conclusions: Our findings demonstrated that treating overt hyperthyroidism in pregnancy is mandatory and appears to reduce some potential maternal-fetal complications, despite there still being a residual risk of negative outcomes.

Keywords: hyperthyroidism, pregnancy, treatment, meta-analysis, maternal, fetal
Study Selection
Two reviewers performed independent eligibility assessments to select the studies using predefined inclusion and exclusion criteria. Any divergence was resolved by consensus or consulting a third reviewer. The inclusion criteria were: (I) pregnant women who have been diagnosed and treated with hyperthyroidism during pregnancy and for whom at least one pregnancy outcome has been assessed and (II) randomized controlled trials (RCTs) or non-randomized trials (NRS) or prospective or retrospective cohort studies with ATD treatment in one comparison arm regardless of the patients’ number. The exclusion criteria were: (I) non-human studies, (II) letters, reviews, case reports, editorials, (III) studies without full text, and (IV) studies from which the necessary data could not be extracted from the pooled results.

Quality Assessment
Study quality was assessed using the Newcastle-Ottawa scale to assess the quality of non-randomized studies in meta-analyses, and certainty assessment was performed using GRADE (13, 14). Disagreements were discussed between the investigators until a consensus was reached.

Data Extraction
One reviewer extracted all relevant information from acceptable studies, including design, sample size, population details, recruitment process, hyperthyroidism exposure, method of treatment, and outcomes. If data were reported in separate metrics, extracted outcome data were converted to a standard metric to estimate treatment effects.

Statistical Analysis
Statistical analyses were performed using the Review Manager software, version 5.4 (RevMan 5.4; Cochrane Collaboration, Oxford, UK). Dichotomous data were analyzed by computing risk differences (RD) with fixed- and random-effect models employed according to the level of heterogeneity. Sensitivity analysis with funnel plot for ≥50% heterogeneity was not performed because, as a rule of thumb, tests for funnel plot asymmetry should be used only when at least ten studies are included in the meta-analysis. Also, the power of the tests is low when there are fewer studies.

RESULTS
Study Selection
After searching five databases and exploring reference lists, 1,225 potential studies were identified. The studies were uploaded to Endnote, where duplicates were excluded. After the exclusions, seven studies contained enough data to be included in a meta-analysis (Figure 1).

Quality Assessment
All seven studies were considered as high quality by the Newcastle-Ottawa scale, as they scored between 7 and 8 (Table 1). Due to the high score, all studies were included in the systematic review and meta-analysis.

Studies Characteristics
All included studies were based on a retrospective cohort conducted in India, Hungary, Thailand, Israel, Finland, and Denmark. The sample sizes ranged from 400 to 1,062,862, and the mean age of studies ranged from 25.5 to 30. The definition of hyperthyroidism during pregnancy varied among the included studies, but the studies clearly expressed the treatment of these women with antithyroid drugs (Table 2).

Study Findings
No study included the assessment of all eligible outcomes. Data describing the presence of pre-eclampsia cases were available in six out of the seven eligible trials studies; data on gestational diabetes mellitus in five studies; fetal growth retardation, stillbirth, and premature birth in four studies; abruptio placenta data were available in three studies and spontaneous abortion, postpartum hemorrhage, and low birth weight in only two studies.

Meta-Analysis of Selected Studies
Among all outcomes evaluated, only preeclampsia, low birth weight, miscarriage and preterm delivery showed a statistically significant difference. The pooled data from the network meta-analysis showed that euthyroid pregnant women, compared to pregnant women who underwent treatment for hyperthyroidism during pregnancy, had a lower incidence of preeclampsia: 4.3% vs. 10.2% (RD=0.04; 95% CI: 0.01 to 0.08; I² = 66%; p=0.01) (Figure 2); low birth weight fetuses: 10.6% vs. 26.4% (RD=0.08; 95% CI: 0.01 to 0.16; I² = 0%; p=0.03) (Figure 3); spontaneous abortions: 13.6% vs. 16% (RD=0.03; 95% CI: 0.02 to 0.04; I² = 0%; p< 0.00001) (Figure 4) and, premature birth: 4.0% vs. 9.8% (RD=0.03; 95% CI: 0.01 to 0.05; I² = 38%; p=0.001) (Figure 5). Random-effects analysis method was used to adjust for inter-study heterogeneity and certainty assessment was very low for all outcomes (Table 3).

For the other outcomes evaluated, the pooled data of the network meta-analysis did not show statistically significant difference between the groups, as follows: abruptio placentae (RD=0.00; 95% CI: -0.01 to 0.01; I² = 0%; p=0.94), fetal growth retardation (RD=-0.02; 95% CI: -0.05 to 0.09; I² = 67%; p=0.61), gestational diabetes mellitus (RD=0.02; 95% CI: -0.00 to 0.03; I² = 13%; p=0.08), postpartum hemorrhage (RD=-0.00; 95% CI: -0.03 to 0.03; I² = 0%; p=0.95) and stillbirth (RD=-0.00; 95% CI: -0.00 to 0.00; I² = 0%; p=0.34). Random-effects analysis method was used to adjust for inter-study heterogeneity when necessary and certainty assessment was also very low for all outcomes (Table 3).

DISCUSSION
According to the 2017 ATA guidelines, poor control of thyrotoxicosis is associated with pregnancy loss, pregnancy-induced hypertension, prematurity, low birth weight, intrauterine growth restriction, stillbirth, thyroid storm, and...
maternal congestive heart failure (3). Unfortunately, there are little data on the effect of controlling thyrotoxicosis during pregnancy on maternal outcomes. Moreover, the risk for adverse maternal outcomes in women who had overt hyperthyroidism treated with ATD during pregnancy differs in various studies, which may be due to differences in inclusion criteria, sample size, and study design (5-11).

The present meta-analysis compared almost 6,000 pregnant women treated for hyperthyroidism with 1.3 million euthyroid pregnant women, demonstrating that the treatment for hyperthyroidism and restoration of the euthyroid state can supposedly reduce the incidence of five essential outcomes: placental abruption, delayed fetal growth, gestational diabetes, postpartum hemorrhage, stillbirth.

Pre-eclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. Pre-eclampsia incidence range from 2-7.5%; some risk factors are hypertension, obesity, diabetes mellitus, age, and race (15, 16). Hyperthyroidism is a well-known risk factor for pre-eclampsia, especially poorly controlled (5, 17). In addition, hyperthyroidism could aggravate a preexisting condition (e.g., hypertension) by predisposing to pre-eclampsia, or it can even trigger pre-eclampsia. Our data show that the development of pre-eclampsia was 4% lower in the pregnancies of euthyroid women.
| Author          | Year | Country  | Design                  | Founding Source                                                                 | Participants (Database)                                                                 | Mean (age) | Study Size (n) | Intervention Groups | N Control Groups | N | Follow-up (years) | Hypertireoidism During Pregnancy (Definition)                                                                 |
|-----------------|------|----------|-------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------|----------------|-------------------|------------------|---|------------------|-----------------------------------------------------------------------------------------------------------------|
| Ajmani SN et al. | 2014 | India    | Prospective Cohort      | Department of obstetrics and gynecology at Kasturba Hospital                    | Hyperthyroidism treated                                                                  | 27.53      | 400            | 2                 | Euthyroidism     | 347 | 01               | High Free T4 (≥2.0 ng/dl) with decreased TSH (≤0.2 IU/l)                                                     |
| Banhindy F et al. | 2011 | Hungary  | Retrospective Cohort    | Hungarian Congenital Anomaly Registry (HCAR)                                 | Hyperthyroidism treated                                                                  | 25.5       | 60,994         | 187               | Euthyroidism     | 60,807 | 16              | Thyrotoxicosis with diffuse goitre [Graves’ disease, toxic diffuse goitre], Thyrotoxicosis with toxic single thyroid nodule, and Thyrotoxicosis with toxic multinodular goitre |
| Luewan S et al.  | 2011 | Thailand | Retrospective Cohort    | Maternal–Fetal Medicine Unit, Chiang Mai University and medical records of the patients. | Hyperthyroidism treated                                                                  | 28.98      | 563            | 180               | Euthyroidism     | 360 | 14               | Pregnant women diagnosed for hyperthyroidism by endocrinologist based on the clinical manifestations and endocrine laboratory confirmation |
| Pillar N et al.  | 2010 | Israel   | Retrospective Cohort    | Soroka University Medical Centre                                               | Hyperthyroidism treated                                                                  | 26.5       | 185,825        | 189               | Euthyroidism     | 185,636 | 19              | Overactive thyroid gland, resulting in the overproduction and, thus, excess of circulating free thyroid hormones (triiodothyronine, thyroxine, or both) |
| Sahu MT et al.   | 2010 | India    | Prospective Cohort      | King George Medical University, and all India Institute of Medical Sciences    | Hyperthyroidism treated                                                                  | 26.0       | 633            | 5                 | Euthyroidism     | 552 | 03               | Elevation in free T4 with an undetectable serum TSH                                                                   |
| Turunen S et al. | 2020 | Finland  | Retrospective Cohort    | Medical Birth Register (MBR) and supplemented with information from the Prescription Register, the Hospital Discharge Register and the Register on Congenital Malformations. | Hyperthyroidism treated                                                                  | 27.5       | 571,785        | 580               | Euthyroidism     | 550,860 | 09              | The ICD-10 code E05 (all digits) and the ICD-9/ICD-8 code both 242                                                 |
| Andersen SL et al. | 2014 | Denmark  | Retrospective Cohort    | Danish nationwide registers                                                    | Hyperthyroidism treated                                                                  | 30.0       | 1,062,862      | 5,229             | Euthyroidism     | 836,905 | 11              | ICD-8: 242.00–242.29 and ICD-10: E05.0–E05.9 (excluding thyrotoxicosis factitia (E05.4), overproduction of TSH (E05.8A) and thyrotoxic heart disease (E05.9A)) |
Gestational diabetes mellitus is also an important outcome with several impacts on maternal health. Obesity is the major risk factor for diabetes mellitus (15, 16, 18). Also, hyperthyroidism is a well-known cause of increased insulin resistance and glucose levels. Both hormonal and immunologic conditions are related to this phenomenon (19). This meta-analysis suggests that overt hyperthyroidism treatment mitigates the deleterious effect of excessive thyroid hormone on glucose metabolism, preventing an increased risk of gestational diabetes mellitus (5, 6, 8–10).

Spontaneous abortion is a tragic situation during pregnancy. Chromosomal abnormality is the single most common cause involved in approximately half of all cases of early spontaneous abortion and is also related to stillbirth (20). In addition, uncontrolled hyperthyroidism during pregnancy is a risk factor, although the molecular mechanism underlying this association is still not well understood (3). Although small but significant, our results showed that euthyroid pregnant women had 3% fewer events of spontaneous abortions.

One of the critical consequences of uncontrolled hyperthyroidism during pregnancy is low birth weight, which may be directly or indirectly related to maternal hyperthyroidism (21). Maternal hyperthyroidism may reduce fetal nutrition or act as a predisposing factor for other conditions that will cause these outcomes, similar to pregnancy-induced hypertension and maternal congestive heart failure (22). In women with GD, maternal TRAb passage to the placenta can induce low birth weight (3). Although overt hyperthyroidism was medicated with ATD, and presumably it was controlled; euthyroid pregnant women had 8% lower occurrence of low birth weight.

Placental abruption is the early separation of the placenta from the lining of the uterus before completing the second stage of labor (23). The primary cause is impairment of the vascular structures that support the placenta (24). Hyperthyroidism can predispose to hypertension, one of the most critical risk factors of placental abruption (3). Correcting hyperthyroidism during pregnancy attenuates this predisposition, resulting in no differences between hyperthyroid-treated women and euthyroid controls (5, 8, 10).

Postpartum hemorrhage is the most common cause of maternal mortality worldwide, and the hyperthyroid state contributes to coagulation disorders, acting directly on the gene transcription of coagulation proteins and altering the clot's structure (25, 26). In addition, hyperthyroidism may cause a hyper-dynamic state and favor bleeding. Our data demonstrated that controlling hyperthyroidism equals the risk of postpartum hemorrhage compared to the control group (5, 7).

The World Health Organization defines premature birth as births before 37 completed weeks of gestation (27). Premature birth rates range from 3 to 14% in low-risk pregnancies. Maternal conditions, including hyperthyroidism, and other conditions such as pre-eclampsia, pre-gestational and gestational diabetes, and cervical incompetence may increase this incidence (28, 29). This meta-analysis showed that even with the treatment of hyperthyroidism, the occurrence of preterm birth was 3% lower in euthyroid pregnant women (5, 7, 9, 10).

This meta-analysis shows an excess risk of hyperthyroid-treated women in four endpoints (pre-eclampsia, low birth weight, placentation, and preterm birth).
weight, spontaneous abortion, and premature birth) in comparison to euthyroid women. The differences were slight, ranging from 3 to 8%, however significant. The deleterious effect of hyperthyroidism affects the three trimesters of gestation, in the first-trimester spontaneous abortion and during the second and third-trimester pre-eclampsia, low birth weight, and premature birth. The mechanisms involved may be several and may be directly or indirectly related to hyperthyroidism, as discussed above. Also, other causes can be related to these negative outcomes, such as other autoimmune conditions associated...
### TABLE 3 | GRADE - certainty assessment.

| No of studies | Study design   | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | GRADE assessment | Effect | Certainty |
|---------------|----------------|--------------|---------------|--------------|-------------|----------------------|------------------|--------|-----------|
| 6             | observational studies | not serious  | not serious   | not serious  | serious\(^a\,b\) | none                | 117/1143 (10.2%)  | 34546/798562 (4.3%) | not estimable | Very low |
|               |                |              |              |              |             |                      |                  |                    |           |
| 2             | observational studies | not serious  | not serious   | not serious  | serious\(^a\)   | none                | 48/182 (26.4%)   | 75/707 (10.6%)   | not estimable | Very low |
|               |                |              |              |              |             |                      |                  |                    |           |
| 2             | observational studies | not serious  | not serious   | not serious  | serious\(^a\)   | none                | 886/5231 (16.9%) | 110928/837252 (13.2%) | not estimable | Very low |
|               |                |              |              |              |             |                      |                  |                    |           |
| 4             | observational studies | not serious  | not serious   | not serious  | serious\(^a\)   | none                | 74/765 (9.7%)    | 21704/552035 (3.9%) | not estimable | Very low |
|               |                |              |              |              |             |                      |                  |                    |           |
| 3             | observational studies | not serious  | not serious   | not serious  | serious\(^a\)   | none                | 15/771 (1.9%)    | 14373/736843 (2.0%) | not estimable | Very low |
|               |                |              |              |              |             |                      |                  |                    |           |
| 4             | observational studies | not serious  | not serious   | not serious  | serious\(^a\,b\) | none                | 30/376 (8.0%)    | 4951/186895 (2.6%) | not estimable | Very low |
|               |                |              |              |              |             |                      |                  |                    |           |
| 5             | observational studies | not serious  | not serious   | not serious  | serious\(^a\)   | none                | 78/963 (8.1%)    | 59618/798202 (7.5%) | not estimable | Very low |
|               |                |              |              |              |             |                      |                  |                    |           |
| 2             | observational studies | not serious  | not serious   | not serious  | serious\(^a\)   | none                | 4/182 (2.2%)     | 28/707 (4.0%)     | not estimable | Very low |
|               |                |              |              |              |             |                      |                  |                    |           |
| 4             | observational studies | not serious  | not serious   | not serious  | serious\(^a\)   | none                | 19/5991 (0.3%)   | 4453/1388472 (0.3%) | not estimable | Very low |

\(^a\) means “Type of study design” and \(^b\) means “Heterogeneity > 50%.”
with GD (30). Also, GD TRAb could have essential participation in negative outcomes. TRAb passage through the placenta and the action in the thyroid fetus’ gland also can determine the increase of these outcomes (31–33), especially in the third trimester. None of the studies evaluated in the meta-analysis mentioned the TRAb titers during treatment. The control of hyperthyroidism and the decrease in TRAb titers do not always present in the same period (34); thus, TRAb can cause fetus’ hyperthyroidism even with maternal thyroid levels normal.

Despite our attempts to eliminate potential biases, this systematic review has limitations. First, because some studies did not specify if hyperthyroidism was treated, we had to exclude many patients from the final analyses (35–46). Second, it is important to emphasize that in carrying out this meta-analysis, we only used studies that showed the treatment of overt hyperthyroidism during pregnancy. Unfortunately, some studies are not specific about the degree of control of hyperthyroidism, we presumed that an euthyroid state was reached and maintained in all treated patients. Also, some studies may have started treatment after the first trimester. Third, the quality of evidence evaluated by the GRADE tool showed a very low certainty of the evidence for all outcomes. The main weak point in the quality of evidence was the type of study design, leading to a high level of imprecision. In addition, we were unable to examine data on subclinical hyperthyroidism and gestational thyrotoxicosis, limiting this meta-analysis to overt hyperthyroidism.

No meta-analysis or systematic review has been published on this topic to our knowledge. In conclusion, treatment of overt hyperthyroidism in pregnancy is mandatory and appears to reduce some potential maternal-fetal complications. However, there is a residual risk of negative results even when overt hyperthyroidism is treated. This information will help doctors and patients manage pregnancy, especially those who needed to treat hyperthyroidism during this process.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article_supplementary material. Further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

JA: made considerable contributions to the design and postulation of the study, the definition of technical content, literature research, data analysis, statistical analysis, manuscript preparation, drafting, writing, critical review, and approval of the manuscript final version for publication. WB: were involved in the data analysis, statistical analysis, manuscript preparation, writing, drafting, critical review for important intellectual content. LW: Manuscript preparation, writing, drafting, critical review for important intellectual content, and approval of the manuscript final version for publication. DV: provided support for the entire process of developing and reviewing this systematic review and approval of the manuscript final version for publication. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global Epidemiology of Hyperthyroidism and Hypothyroidism. *Rev Endocrino* (2018) 14(5):301–16. doi: 10.1038/rendo.2018.18

2. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. T(4), and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab* (2002) 87(2):489–99. doi: 10.1210/jcem.87.2.8182

3. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. *Thyroid* (2017) 27(3):315–89. doi: 10.1089/thy.2016.0457

4. Mestman JH. Evaluating and Managing Postpartum Thyroid Dysfunction. *Medscape Women’s Health* (1997) 2(7):3.

5. Ajmani SN, Aggarwal D, Bhattacharjee, Sharma M, Sarabhai V, Paul M. Prevalence of Overt and Subclinical Thyroid Dysfunction Among Pregnant Women and its Effect on Maternal and Fetal Outcome. *J Obstet Gynaecol India* (2014) 64(2):105–10. doi: 10.1007/s13224-013-0487-y

6. Bánhidy F, Puhó EH, Czeizel AE. Possible Association Between Hyperthyroidism in Pregnant Women and Obstructive Congenital Abnormalities of Urinary Tract in Their Offspring–A Population-Based Case-Control Study. *J Matern Fetal Neonatal Med* (2011) 24(2):305–12. doi: 10.3109/14767058.2010.487142

7. Luwero S, Chakrabut P, Tongsong T. Outcomes of Pregnancy Complicated With Hyperthyroidism: A Cohort Study. *Arch Gynecol Obstet* (2011) 283(2):243–7. doi: 10.1007/s00404-010-1362-z

8. Pillar N, Levy A, Holcmb G, Sheiner E. Pregnancy and Perinatal Outcome in Women With Hyperthyroidism. *Int J Gynaecol Obstet* (2010) 108(1):61–4. doi: 10.1016/j.ijgo.2009.08.006

9. Sahu MT, Das V, Mittal S, Agarwal A, Sahu M. Overt and Subclinical Thyroid Dysfunction Among Indian Pregnant Women and Its Effect on Maternal and Fetal Outcome. *Arch Gynecol Obstet* (2010) 281(2):215–20. doi: 10.1007/s00404-009-1105-1

10. Turunen S, Vääräsmäki M, Lahesmaa-Korpinen AM, Leinonen MK, Gissler M, Männistö T, et al. Maternal Hyperthyroidism and Pregnancy Outcomes: A Population-Based Cohort Study. *Clin Endocrinol (Oxf)* (2020) 93(6):721–8. doi: 10.1111/cen.14282

11. Andersen SL, Olsen J, Wu CS, Laurberg P. Spontaneous Abortion, Stillbirth and Hyperthyroidism: A Danish Population-Based Study. *Eur Thyroid J* (2014) 3(3):164–72. doi: 10.1159/000365101

12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. *BMJ* (2021) 372:n71. doi: 10.1136/bmj.n71

13. Wells GA, Shea B, O’Connel D, Peterson J, Welch V, Losos M, et al. *The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses* (2009). Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.

14. Dijkers M. Introducing GRADE: A Systematic Approach to Rating Evidence in Systematic Reviews and to Guideline Development. *KT Update* (2013) 1(5):1–9.

15. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. *JAMA Netw Open* (2021) 4(3):e218401. doi: 10.1001/jamanetworkopen.2021.8401

16. Mayrink J, Souza RT, Feitosa FE, Rocha Filho EA, Leite DF, Vettorazzi J, et al. Incidence and Risk Factors for Preeclampsia in a Cohort of Healthy

Frontiers in Endocrinology | www.frontiersin.org 9 June 2022 | Volume 13 | Article 800257
Nulliparous Pregnant Women: A Nested Case-Control Study. Sci Rep (2019) 29(1):9517. doi: 10.1038/s41598-019-46011-3

Korevaar TJ, Steegers EA, Chaker L, Medici M, Jaddoe VW, Visser TJ, et al. The Risk of Preeclampsia According to High Thyroid Function in Pregnancy Differs by hCG Concentration. J Clin Endocrinol Metab (2016) 101(12):4037–43. doi: 10.1210/jc.2016-2397

Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, et al. Maternal Obesity and Risk of Gestational Diabetes Mellitus. Diabetes Care (2007) 30(8):2070–6. doi: 10.2337/dci06-2559a

Miyauchi S, Matsuura B, Ueda T, Eguchi T, Tamaru M, Yamamoto S, et al. Interleukin-18 Induces Insulin Resistance in the Hyperthyroid State. Endocrinol J (2013) 60(4):449–55. doi: 10.1507/endocr.e12-0136

Feodor Nilsson S, Andersen PK, Strandberg-Larsen K, Nybo Andersen AM. Risk Factors for Miscarriage From a Prevention Perspective: A Nationwide Follow-Up Study. BJOG (2014) 121(11):1375–84. doi: 10.1111/1471-0528.12694

Phojoaroenchanchai M, Srisuadadporn S, Peerapadit T, Vannasaeng S, Niyantnan W, Boonnamsiri V, et al. Effect of Maternal Hyperthyroidism During Late Pregnancy on the Risk of Neonatal Low Birth Weight. Clin Endocrinol (Oxf) (2001) 54(3):365–70. doi: 10.1046/j.1365-2265.2001.01224.x

Stagnaro-Green A. Overt Hyperthyroidism and Hyperthyroidism During Pregnancy. Clin Obstet Gynecol (2011) 54(3):478–87. doi: 10.1097/GRF.0b013e31822725f2

Downes KL, Grantly KL, Shenassa ED, Maternal, Labor, Delivery, and Perinatal Outcomes Associated With Placental Abruption: A Systematic Review. Am J Perinatol (2017) 34(10):935–57. doi: 10.1056/ajpmt.2017.10.004

Boisramé T, Sananès N, Fritz G, Boudier E, Aissi G, Favre R, et al. Maternal Abruption: Risk Factors, Management and Maternal-Fetal Prognosis. Cohort Study Over 10 Years. Eur J Obstet Gynecol Reprod Biol (2019) 179:100–4. doi: 10.1016/j.ejogrb.2019.04.026

Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, et al. The Global, Regional, and National Levels and Causes of Maternal Mortality During 1990–2013: A Systematic Analysis for the Global Burden of Disease Study 2013. Lancet (2014) 384(9947):980–1004. doi: 10.1016/s0140-6736(14)60969-6

Elbers LPB, Flers E, Cazeneve SC. The Influence of Thyroid Function on the Coagulation System and Its Clinical Consequences. J Thromb Haemost (2016) 16 (4):634–45. doi: 10.1111/j.1377

WHO: Recommended Definitions, Terminology and Format for Statistical Tables Related to the Perinatal Period and Use of a New Certificate for Cause of Perinatal Deaths. Modifications Recommended by FIGO as Amended October 14, 1976. Acta Obstet Gynecol Scand (1977) 56(3):247–53.

Kiserud T, Paggiog G, Carroll G, Widmer M, Carvalho J, Neerup Jensen L, et al. The World Health Organization Fetal Growth Charts: A Multinational Longitudinal Study of Ultrasonic Biometric Measurements and Estimated Fetal Weight. PLoS Med (2017) 14(1):e1002220. doi: 10.1371/journal.pmed.1002220

Ferrero DM, Larson J, Jacobsson B, Di Renzo GC, Norman JE, Martin JN Jr, et al. Maternal Obesity and Risk of Gestational Diabetes Mellitus. Am J Obstet Gynecol (2001) 54(3):365–70. doi: 10.1016/s0002-9378(01)00226-7

Fekri M, Omar S, Menif O, Tanfous NB, Slimane H, Zouari F, et al. Thyroid Disorders in Pregnancy: Frequency and Association With Selected Diseases and Obstetrical Complications in Tunisian Women. Clin Biochem (2008) 41 (12):927–31. doi: 10.1016/j.clinbiochem.2008.05.002

Mannistö T, Mendola P, Grewal L, Xie Y, Chen Z, Laughon SK. Thyroid Disorders and Adverse Pregnancy Outcomes in a Contemporary US Cohort. J Clin Endocrinol Metab (2013) 98(7):2725–33. doi: 10.1210/jc.2012-2433

Medici M, Korevaar TJ, Schalekamp-Timmermans S, Gaillard R, de Rijke YB, Visser WE, et al. Maternal Early-Pregnancy Thyroid Function Is Associated With Subsequent Hypertensive Disorders of Pregnancy: The Generation R Study. J Clin Endocrinol Metab (2014) 99(12):E2991-8. doi: 10.1210/jc.2014-1505

Moradinazar M, Najafi F, Nazar ZM, Hamzeh B, Pasdar Y, Shahbka E. Lifetime Prevalence of Abortion and Risk Factors in Women: Evidence From a Cohort Study. J Pregnancy (2020) 2020:4871494. doi: 10.1155/2020/4871494

Ohashi M, Furukawa S, Michikata K, Kai K, Sameshima H, Benoue T. Risk-Based Screening for Thyroid Dysfunction During Pregnancy. J Pregnancy (2013) 2013:619718. doi: 10.1155/2013/619718

Saki F, Dabbaghmanesh MH, Ghaemi SZ, Forouhari S, Ranbar Omrani G, Bahkshayeshkaram M. Thyroid Function in Pregnancy and Its Influences on Maternal and Fetal Outcomes. Int J Endocrinol Metab (2014) 12(4):e19378. doi: 10.5812/ijem.19378

Shahid MM, Rahman KMT, Gomes RR, Ferdous M, Ferdousi S, Zahan T. Association of Gestational Diabetes Mellitus and Thyroid Status During Pregnancy. PloS One (2017) 12(4):e0184545. doi: 10.1371/journal.pone.0184545

Singh V, Natu N, Gupta AS. Comparison of Maternal and Perinatal Outcome in Pregnancy With Altered Thyroid Profile and Euthyroid Patients: A Prospective, Observational and Case Control Study in a Tertiary Care Centre. Int J Reprod Contracept Obstet Gynecol (2019) 8(4):1594–600. doi: 10.18203/2320-1770.ijrco20191224

Su PY, Huang K, Hao HJ, Xu YQ, Yan SQ, Li T, et al. Maternal Thyroid Function in the First Twenty Weeks of Pregnancy and Subsequent Fetal and Infant Development: A Prospective Population-Based Cohort Study in China. J Clin Endocrinol Metab (2011) 96(10):3234–41. doi: 10.1210/jc.2011-0274

Yang J, Liu Y, Liu H, Zheng H, Li X, Zha L, et al. Associations of Maternal Iodine Status and Thyroid Function With Adverse Pregnancy Outcomes in Henan Province of China. J Trace Elem Med Biol (2018) 47:104–10. doi: 10.1016/j.jteemb.2018.01.013

You SH, Cheng PI, Chung TT, Kuo CF, Wu HM, Chu PH. Population-Based Trends and Risk Factors of Early- and Late-Onset Preeclampsia in Taiwan 2001-2014. BMC Pregnancy Childbirth (2018) 18(1):189. doi: 10.1186/s12884-018-1845-7

Zhang Y, Li Y, Shan Z, Xu Y, Li C, Xie X, et al. Association of Overt and Subclinical Hyperthyroidism During Weeks 4-8 With Adverse Pregnancy Outcomes. J Women’s Health (Larchmt) (2019) 28(6):842–8. doi: 10.1089/jwh.2018.7180

Conflict of Interest: The reviewer FEP declared a shared affiliation with the author DV to the handling editor at the time of review.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Alves Junior, Bernardo, Ward and Villagelin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.